Major publications

• Matkarimov, B.T., Zharkov, D.O., and SAPARBAEV, M.K. (2019) Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage. Mutagenesis, Nov 29. pii: gez045. doi: 10.1093/mutage/gez045/5646155.

Composition of the Board of directors

Members by right

• MARC GUILLAUME
  Île-de-France, Préfet de Paris Chairman, Prefect of the Ile-de-France region, Prefect of Paris
• GENEVIÈVE CARPE
  Departmental Councillor, Val-de-Marne
• SAMAKE HAMIDOU
  Member of Paris Council
• MARC HUMBERT
  Dean of the Faculty of Medicine
• NICOLAS ALBIN
  Representative of the Ministry of Higher Education and Research
• Pr BRUNO QUESNEL
  Representative of the French National Cancer Institute
• MIREILLE GUYADER

Mechanisms of DNA Repair and Carcinogenesis

This team belongs to the UMR 9019 Genome Integrity and Cancers.

Urology Committee

Oncologists: Pr Laurence Albiges, Dr Karim Amrane, Dr Alice Bernard Tessier, Dr Solenn Barraud, Dr Mario Di Palma, Dr Bernard Escudier, Dr Alina Fuerea, Dr Ronan Flippot, Pr Yohann Loriot, Dr Alexandre Megherbi, Dr Natacha Naoun, Dr Anna Patrikidou, Dr Cédric Pobel, Dr Macarena Rey Cardenas, Dr Aurélia Robert,  Dr Jacopo Uliano
 
Oncology Radiotherapy: Pr Pierre Blanchard, Dr Youssef Ghannam, Dr Mario Terlizzi, Irfane Issoufaly, Federica Medici, Ines Chaffai Nouri
 

En cas de cancer localisé

Il existe plusieurs moyens pour traiter un cancer de la prostate :

La chirurgie

Le traitement chirurgical du cancer de la prostate consiste à enlever la prostate et les vésicules séminales (prostatectomie radicale). Si la chirurgie est nécessaire, elle pourra être pratiquée dans certains cas à Gustave Roussy ou à l'hôpital Bicêtre, partenaire de Gustave Roussy.

Treatment of prostate cancer

Prostate cancer is the commonest cancer in men, with more than 70,000 new cases annually in France. This is usually a slowly developing cancer. It can be completely silent or may be the cause of urinary symptoms such as difficulty in passing urine or frequency of micturition.

Gustave Roussy is a non-profit making private health establishment with a public role.
As a Cancer Centre, its status derives from Directive n° 45-2221 of the 1st October 1945, modified by Directive n° 2005-406 of the 2nd May 2005 and by the "HPST" Law of 21st July 2009 on hospital reform with a bearing on patients, health and local authorities. 

Gustave Roussy is a member of Unicancer, an organisation to which all French Cancer Centres belong.

International Thoracic Cancer Center Staff

Gustave Roussy

• Fabrice Barlesi, General Director of Gustave Roussy, medical oncologist
• David Planchard, thoracic oncologist, chairman of the thoracic cancer commitee of Gustave Roussy and president of the International Thoracic Cancer Center
• Benjamin Besse, medical oncologist, director of clinical research at Gustave Roussy